  Follicle-stimulating hormone (FSH) is produced in the pituitary and is
essential for reproduction. It specifically binds to a membrane receptor (FSHR)
expressed in somatic cells of the gonads. The FSH/FSHR system presents many
peculiarities compared to classical G protein-coupled receptors (GPCRs). FSH is
a large naturally heterogeneous heterodimeric glycoprotein. The FSHR is
characterized by a very large NH2-terminal extracellular domain, which binds
the FSH and participates to the activation/inactivation switch of the receptor.
Once activated, the FSHR couples to G{\alpha}s and, in some instances, to other
G{\alpha} subunits. G protein-coupled receptor kinases and \beta-arrestins are
also recruited to the FSHR and account for its desensitization, the control of
its trafficking and its intracellular signalling. Of note, the FSHR
internalization and recycling are very fast and involve very early endosomes
instead of early endosomes. All the transduction mechanisms triggered upon FSH
stimulation lead to the activation of a complex signalling network that
controls gene expression by acting at multiple levels. The integration of these
mechanisms leads to context-adapted responses from the target gonadal cells,
but also indirectly affects the fate of germ cells. Depending of the
physiological/developmental stage, FSH elicits proliferation, differentiation
or apoptosis in order to maintain the homeostasis of the reproductive system.
Pharmacological tools targeting FSHR recently came to the fore and open
promising prospects both for basic research and therapeutic applications. This
paper provides an updated review of the most salient aspects and peculiarities
of FSHR biology and pharmacology.
